CNTX — Context Therapeutics Share Price
0.000.00%
Last trade - 00:00HealthcareMicro Cap
- $1.57m
- $122.88m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -62.26% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2013 | 2014 | 2015 | 2016 | 2017 | 2018E | 2019E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company, which is engaged in advancing T cell engaging (TCE) bispecific antibodies (bsAb) for solid tumors. It is building a portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE, CT-95, a Mesothelin (MSLN) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (Nectin-4) x CD3 TCE. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. CT-95 is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. Nectin-4 is a target for cancer therapy using a traditional antibody-drug conjugate, but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the acidic tumor microenvironment.
Directors
- Last Annual
- December 31st, 2017
- Last Interim
- September 30th, 2018
- Incorporated
- February 26th, 2015
- Public Since
- October 20th, 2021
- No. of Shareholders
- 48
- No. of Employees
- 12
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 89,704,194
- Address
- 2001 Market Street, Suite 3915 Unit #15, PHILADELPHIA, 19103
- Web
- https://www.contexttherapeutics.com/
- Phone
- +1 2672257416
- Auditors
- CohnReznick LLP
Upcoming Events for CNTX
Context Therapeutics Inc at Citizens JMP Life Sciences Conference
Context Therapeutics Inc Annual Shareholders Meeting
Context Therapeutics Inc Annual Shareholders Meeting
Similar to CNTX
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Context Therapeutics share price?
As of Today at 20:03 UTC, shares in Context Therapeutics are trading at $0.94. This share price information is delayed by 15 minutes.
How has the Context Therapeutics share price performed this year?
Shares in Context Therapeutics last closed at $0.94 and the price had moved by -31.88% over the past 365 days. In terms of relative price strength the Context Therapeutics share price has underperformed the S&P500 Index by -37.13% over the past year.
What are the analyst and broker recommendations for Context Therapeutics?
There is no consensus recommendation for this security.
Find out moreWhat is the Context Therapeutics dividend yield?
Context Therapeutics does not currently pay a dividend.
Does Context Therapeutics pay a dividend?
Context Therapeutics does not currently pay a dividend.
When does Context Therapeutics next pay dividends?
Context Therapeutics does not currently pay a dividend.
How do I buy Context Therapeutics shares?
To buy shares in Context Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Context Therapeutics?
As of the previous close price of $0.94, shares in Context Therapeutics had a market capitalisation of $1.57m.
Where are Context Therapeutics shares listed?
Here are the trading details for Context Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CNTX
What kind of share is Context Therapeutics?
Based on an overall assessment of its quality, value and momentum Context Therapeutics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Context Therapeutics share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Context Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Context Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -57.66%.
As of the last closing price of $0.94, shares in Context Therapeutics were trading -38.95% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Context Therapeutics PE Ratio?
The Context Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.94.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Context Therapeutics?
We do not have data on Context Therapeutics' directors